ValuEngine downgraded shares of Synthetic Biologics Inc (NYSEMKT:SYN) from a sell rating to a strong sell rating in a research report released on Friday morning.

Several other brokerages also recently weighed in on SYN. Zacks Investment Research upgraded shares of Synthetic Biologics from a hold rating to a buy rating and set a $0.75 target price for the company in a research note on Wednesday, August 9th. William Blair reiterated an outperform rating and set a $5.00 target price on shares of Synthetic Biologics in a research note on Monday, May 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Synthetic Biologics presently has an average rating of Hold and an average price target of $3.92.

Synthetic Biologics (NYSEMKT SYN) opened at 0.75 on Friday. The firm’s 50 day moving average price is $0.58 and its 200-day moving average price is $0.61. The stock’s market cap is $96.19 million. Synthetic Biologics has a 1-year low of $0.41 and a 1-year high of $1.90.

Synthetic Biologics (NYSEMKT:SYN) last announced its earnings results on Thursday, August 3rd. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03. On average, equities analysts anticipate that Synthetic Biologics will post ($0.17) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Synthetic Biologics Inc (SYN) Stock Rating Lowered by ValuEngine” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.dailypolitical.com/2017/09/04/synthetic-biologics-inc-syn-stock-rating-lowered-by-valuengine.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of SYN. Norges Bank purchased a new position in Synthetic Biologics during the fourth quarter worth about $356,000. Bank of New York Mellon Corp raised its holdings in Synthetic Biologics by 3.1% during the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock worth $166,000 after purchasing an additional 7,962 shares in the last quarter. UBS Group AG raised its holdings in Synthetic Biologics by 10.3% during the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock worth $135,000 after purchasing an additional 20,038 shares in the last quarter. Creative Planning raised its holdings in Synthetic Biologics by 65.4% during the second quarter. Creative Planning now owns 177,000 shares of the company’s stock worth $100,000 after purchasing an additional 70,000 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in Synthetic Biologics during the second quarter worth about $194,000.

About Synthetic Biologics

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.